中国5,425家实验室2013至2022年临床化学检测内部质量控制变异系数评价
该研究基于2013至2022年每年2月收集的27项常规化学检测项目室内质控数据,评估中国临床化学测量系统的不精密度。参与实验室从2013年的1,777家增至2022年的5,425家,除肌酸激酶和脂肪酶外所有项目CV显著下降。2022年采用四种性能规范计算通过率,部分项目在更严格规范下仍有改进空间。
要点
- 2013至2022年中国临床化学室内质控CV整体持续改善,仅肌酸激酶和脂肪酶未显著下降。
- 2022年甘油三酯、总胆红素、直接胆红素、铁和γ-谷氨酰转移酶在所有规范下通过率>80%。
- 基于1/3允许总误差通过率<80%的9个项目中,除总蛋白外闭管系统CV均低于开管系统。
核心结论
- 中国临床化学室内质控CV整体持续改善,但部分项目在更严格性能规范下仍需改进不精密度。
研究设计与样本
- 基于2013至2022年每年2月收集的27项常规化学检测项目室内质控数据,参与实验室从2013年1,777家增至2022年5,425家。
- 采用四种性能规范计算2022年CV通过率,用箱线图分析CV趋势,用Mann-Whitney U检验或Kruskal-Wallis检验比较组间CV差异。
主要发现
- 除肌酸激酶和脂肪酶外,所有27个项目的CV均显著下降。
- 2022年甘油三酯、总胆红素、直接胆红素、铁和γ-谷氨酰转移酶的通过率在所有目标下均>80%。
- 基于1/3允许总误差通过率<80%的9个项目进一步分析显示,除总蛋白外闭管系统CV均低于开管系统。
- 上述9个项目在三级与非三级医院间、认可与非认可实验室间差异均显著。
关键数值与推荐
- 采用四种性能规范计算2022年CV通过率;基于1/3允许总误差通过率<80%的9个项目被进一步分析。
- 甘油三酯、总胆红素、直接胆红素、铁和γ-谷氨酰转移酶在所有目标下通过率>80%。
临床怎么用
- 检验科可参考本地区或同类实验室CV数据设定室内质控目标,对通过率低的项目优先改进不精密度。
- 闭管系统在多数项目上CV表现优于开管系统,选型时可结合不精密度数据评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical chemistry tests are most widely used in clinical laboratories, and diverse measurement systems for these analyses are available in China. We evaluated the imprecision of clinical chemistry measurement systems based on internal QC (IQC) data. METHODS: IQC data for 27 general chemistry analytes were collected in February each year from 2013 to 2022. Four performance specifications were used to calculate pass rates for CVs of IQC data in 2022. Boxplots were drawn to analyze trends of CVs, and differences in CVs among different groups were assessed using the Mann-Whitney U-test or Kruskal-Wallis test. RESULTS: The number of participating laboratories increased significantly from 1,777 in 2013 to 5,425 in 2022. CVs significantly decreased for all 27 analytes, except creatine kinase and lipase. Triglycerides, total bilirubin, direct bilirubin, iron, and γ-glutamyl transferase achieved pass rates >80% for all goals. Nine analytes with pass rates <80% based on 1/3 allowable total error were further analyzed; the results indicated that closed systems exhibited lower CVs than open systems for all analytes, except total protein. For all nine analytes, differences were significant between tertiary hospitals and non-tertiary hospitals and between accredited and non-accredited laboratories. CONCLUSIONS: The CVs of IQC data for clinical chemistry have seen a continuous overall improvement in China. However, there is ample room for imprecision improvement for several analytes, with stricter performance specifications.
引用
- Wang W, Zhang Z, Zhang C, et al. Evaluation of Coefficients of Variation for Clinical Chemistry Tests Based on Internal Quality Control Data Across 5,425 Laboratories in China From 2013 to 2022. Ann Lab Med. 2023. PMID: 38014482. doi:10.3343/alm.2023.0236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。